Pharmacokinetic Considerations for Selection of HAART in Treatment-Naive HIV-Infected Individuals, 2008: More Than it Seems?
Andrew D. Luber PharmD
Journal of the International Association of Providers of AIDS Care · 2008
doi:10.1177/1545109708315364 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The selection of highly active antiretroviral therapy for treatment-naive HIV-infected individuals is complex. In addition to patient adherence, exposures of antiretroviral agents (ARVs) can be influenced by patient population, gender, drug–drug and drug–food interactions, and comorbid medical conditions. In contrast to pharmacokinetic sampling performed under controlled conditions, ARV exposures in “real-world” clinical practice display substantial interpatient variability. The interactions between ARVs and other medications commonly used by HIV-infected patients could significantly impact ARV exposures and need to be considered when selecting therapies. Pharmacogenomic differences have been identified for a number of ARVs, resulting in increased plasma exposures (efavirenz, nelfinavir) or increased risk for adverse drug events (atazanavir, abacavir, indinavir). Despite increasing populations of HIV-infected females and people 50 years or older, the pharmacokinetics of many ARVs has not been adequately studied in these patient populations. The clinical significance of many of these pharmacokinetic differences is unknown.
Abstract licence: CC BY-NC
References50
40 more references, whose wording the paper’s licence keeps private.
All 50 referencesReads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.